Xilio Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.14 Insider Own7.40% Shs Outstand27.40M Perf Week-8.27%
Market Cap61.82M Forward P/E- EPS next Y-2.91 Insider Trans0.00% Shs Float25.44M Perf Month6.11%
Income-85.50M PEG- EPS next Q-0.84 Inst Own67.90% Short Float / Ratio0.10% / 0.27 Perf Quarter17.39%
Sales- P/S- EPS this Y-37.30% Inst Trans-6.30% Short Interest0.02M Perf Half Y-12.59%
Book/sh4.61 P/B0.53 EPS next Y8.50% ROA-45.60% Target Price21.00 Perf Year-82.88%
Cash/sh5.47 P/C0.44 EPS next 5Y- ROE-55.00% 52W Range2.01 - 16.93 Perf YTD-84.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.65% Beta-
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low20.90% ATR0.30
Employees78 Current Ratio8.40 Sales Q/Q- Oper. Margin- RSI (14)47.38 Volatility18.66% 11.54%
OptionableNo Debt/Eq0.08 EPS Q/Q-18.50% Profit Margin- Rel Volume0.34 Prev Close2.39
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume90.78K Price2.43
Recom1.70 SMA20-2.27% SMA50-3.61% SMA200-39.21% Volume30,836 Change1.67%
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
04:05PM Loading…
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
05:38PM Loading…
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bain Capital Life Sciences Inv10% OwnerDec 10Buy9.6525,000241,2022,805,413Dec 10 08:33 PM
Bain Capital Life Sciences Inv10% OwnerDec 09Buy9.844,01139,4852,780,413Dec 10 08:33 PM
Bain Capital Life Sciences Inv10% OwnerDec 08Buy9.6213,458129,4742,776,402Dec 10 08:33 PM